Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2007-02-01 (19 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MELGVEN (29140), Finistere
SELARL PHARMACIE DE MELGVEN : revenue, balance sheet and financial ratios
SELARL PHARMACIE DE MELGVEN is a French company
founded 19 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MELGVEN (29140),
this company of category PME
shows in 2024 a revenue of 2.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE DE MELGVEN (SIREN 494514151)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
2 235 324 €
2 230 482 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
80 581 €
78 451 €
97 785 €
163 462 €
117 321 €
99 484 €
115 430 €
117 040 €
116 363 €
EBITDA
N/C
96 379 €
106 509 €
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
3.5%
4.4%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL PHARMACIE DE MELGVEN generates positive net income of 81 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 116 k€ -> 81 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
80 581 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 1%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 90%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
1.067%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
89.956%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELARL PHARMACIE DE MELGVEN
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
54.353
36.577
23.968
15.947
10.818
6.275
3.046
2.084
1.067
Financial autonomy
59.097
68.237
75.159
80.603
83.962
85.671
87.989
89.897
89.956
Repayment capacity
None
None
None
None
None
None
0.525
0.379
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
3.886%
3.63%
None%
Sector positioning
Debt ratio
1.072025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Excellent
In 2025, the debt ratio of SELARL PHARMACIE DE MELGVEN (1.07) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
89.96%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Excellent+14 pts over 3 years
In 2025, the financial autonomy of SELARL PHARMACIE DE MELGVEN (90.0%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
0.38 years2024
2023
2024
Q1: 0.52 years
Med: 3.19 years
Q3: 7.6 years
Excellent
In 2024, the repayment capacity of SELARL PHARMACIE DE MELGVEN (0.38) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 381.36. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
381.364
Liquidity indicators evolution SELARL PHARMACIE DE MELGVEN
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
408.781
466.435
437.911
441.218
438.255
390.476
401.193
418.808
381.364
Interest coverage
None
None
None
None
None
None
0.879
0.728
None
Sector positioning
Liquidity ratio
381.362025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Excellent
In 2025, the liquidity ratio of SELARL PHARMACIE DE MELGVEN (381.36) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
0.73x2024
2023
2024
Q1: 0.0x
Med: 2.35x
Q3: 7.73x
Average
In 2024, the interest coverage of SELARL PHARMACIE DE MELGVEN (0.7x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE DE MELGVEN
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
482 007 €
439 375 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
27
28
0
Customer payment term (days)
0
0
0
0
0
0
11
9
0
Supplier payment term (days)
0
0
0
0
0
0
24
17
0
Positioning of SELARL PHARMACIE DE MELGVEN in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE DE MELGVEN is estimated at
1 280 038 €
(range 868 640€ - 2 008 557€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
868k€1280k€2008k€
1 280 038 €Range: 868 640€ - 2 008 557€
NAF 5 année 2025
Valuation method used
Net Income Multiple
80 581 €
×
15.9x
=1 280 039 €
Range: 868 640€ - 2 008 557€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE DE MELGVEN with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE DE MELGVEN
What is the revenue of SELARL PHARMACIE DE MELGVEN ?
The revenue of SELARL PHARMACIE DE MELGVEN in 2024 is 2.2 M€.
Is SELARL PHARMACIE DE MELGVEN profitable?
Yes, SELARL PHARMACIE DE MELGVEN generated a net profit of 81 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE DE MELGVEN ?
The headquarters of SELARL PHARMACIE DE MELGVEN is located in MELGVEN (29140), in the department Finistere.
Where to find the tax return of SELARL PHARMACIE DE MELGVEN ?
The tax return of SELARL PHARMACIE DE MELGVEN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE DE MELGVEN operate?
SELARL PHARMACIE DE MELGVEN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart